NCT03763708

Brief Summary

To characterize the effects of stimulation parameters on pain relief and other cohort specific outcomes.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

9 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 4, 2018

Completed
8 days until next milestone

Study Start

First participant enrolled

December 12, 2018

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 13, 2023

Completed
2 years until next milestone

Results Posted

Study results publicly available

December 31, 2024

Completed
Last Updated

December 31, 2024

Status Verified

December 1, 2024

Enrollment Period

4.1 years

First QC Date

December 3, 2018

Results QC Date

December 9, 2024

Last Update Submit

December 9, 2024

Conditions

Outcome Measures

Primary Outcomes (9)

  • Numeric Pain Rating Scale (NPRS) - Cohort 1

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 5 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 2

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 2 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 3

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 3 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 4

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 5 months

  • Numeric Pain Rating Scale - Cohort 5

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 5 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 6

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 7 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 7

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 8 months

  • Numeric Pain Rating Scale (NPRS) - Cohort 8

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 0.5 months

  • Numeric Pain Rating Scale at Enrollment (NPRS) - Cohort 9

    To characterize the effect of different programmed settings on pain relief. The NPRS will be recorded once or daily over a period of time, where the subjects will rate their pain on a 11-point numeric rating scale of 0 to 10, with 0 representing 'No Pain' and 10 representing 'Worst pain imaginable'. The average overall NPRS pain score prior to the scheduled visit will be used for analysis.

    Up to 1 month

Study Arms (9)

Cohort 1: Low Energy - Continuous

EXPERIMENTAL

Subjects will be programmed to a specific frequency with a long pulse width at various amplitudes

Device: Spinal Cord Stimulation

Cohort 2: Interleaving

EXPERIMENTAL

Determine effects of delivering ping pulses combined with governed pulses while using separate sets of electrodes

Device: Spinal Cord Stimulation

Cohort 3: Cycling Evolve

EXPERIMENTAL

Subjects will be programmed to high dose (HD) stimulation with various cycling parameters

Device: Spinal Cord Stimulation

Cohort 4: Low Energy Cycling 1

EXPERIMENTAL

Effects of decreased pulse widths with increased frequency - with and without cycling parameters

Device: Spinal Cord Stimulation

Cohort 5: Low Energy Cycling 2

EXPERIMENTAL

Effects of decreased pulse widths with increased frequency - with and without cycling parameters (different pulse widths and frequencies than Cohort 4)

Device: Spinal Cord Stimulation

Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)

EXPERIMENTAL

Effects of decreased frequency and therapy cycling parameters

Device: Spinal Cord Stimulation

Cohort 7: Super Cycle

EXPERIMENTAL

Effects of longer cycle duration

Device: Spinal Cord Stimulation

Cohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)

EXPERIMENTAL

Effects of integrating Neuro Sense into DTM programming

Device: Spinal Cord Stimulation

Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow

EXPERIMENTAL

Characteristics of vital signs in DPN participants

Device: Spinal Cord Stimulation

Interventions

Programming

Cohort 1: Low Energy - ContinuousCohort 2: InterleavingCohort 3: Cycling EvolveCohort 4: Low Energy Cycling 1Cohort 5: Low Energy Cycling 2Cohort 6: Differential Targeted Multiplexed-Low Energy Spinal Cord Stimulation (DTM-LE SCS)Cohort 7: Super CycleCohort 8: Differential Targeted Multiplexed (DTM) for Neuro Sense (NS)Cohort 9: Diabetic Peripheral Neuropathy (DPN) Flow

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Implanted with a Medtronic rechargeable neurostimulation system, for a labeled indication, for at least 1 month and expected longevity of neurostimulator is at least 5 months
  • Willing and able to provide signed and dated informed consent
  • Capable of comprehending and consenting in English
  • Willing and able to comply with all study procedures, including diary completion, and visits
  • Able to differentiate between pain associated with the indication for SCS implant and other types of pain

You may not qualify if:

  • Implanted with neurostimulation system for an off-label indication
  • Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results
  • If female, pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study
  • Has untreated major psychiatric comorbidity
  • Has a non-rechargeable neurostimulator where the battery longevity is not able to be estimated with the battery longevity calculator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Center for Pain and Supportive Care

Phoenix, Arizona, 85028, United States

Location

Goodman Campbell Brain and Spine

Carmel, Indiana, 46032, United States

Location

Drez One

Somerset, Kentucky, 42503, United States

Location

Twin Cities Pain Clinic

Edina, Minnesota, 55439, United States

Location

Regional Brain and Spine

Cape Girardeau, Missouri, 63701, United States

Location

Carolinas Research Institute

Huntersville, North Carolina, 28078, United States

Location

Center for Interventional Pain and Spine

Lancaster, Pennsylvania, 17601, United States

Location

Pain Diagnostics and Interventional Care

Sewickley, Pennsylvania, 15143, United States

Location

Northwest Pain Care

Spokane, Washington, 99201, United States

Location

MeSH Terms

Interventions

Spinal Cord Stimulation

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitation

Results Point of Contact

Title
SCS Research Study Team
Organization
Medtronic Neuromodulation

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2018

First Posted

December 4, 2018

Study Start

December 12, 2018

Primary Completion

January 13, 2023

Study Completion

January 13, 2023

Last Updated

December 31, 2024

Results First Posted

December 31, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations